AstraZeneca Keeps R&D Focus, Spins Out Phase II Neuromyelitis Optica MAb Into New Biotech

Six early-stage biologics with potential to treat inflammation and auto-immunity disorders have been spun out of AstraZeneca's biologics arm, MedImmune, into a stand-alone Chinese investor-backed company, Viela Bio, underlining the commitment of the big pharma to its three areas of therapeutic focus.

Vortex
Spinning off non-core assets has been a feature of AstraZeneca's business development • Source: Shutterstock

A biologic, inebilizumab, in Phase II for the treatment of an autoimmune disease, neuromyelitis optica, is the lead compound for a new stand-alone company, Viela Bio, spun-out of AstraZeneca PLC's biologics arm, MedImmune LLC, with financing from a group of Chineseprivate equity funds. The new company is helmed by CEO Bing Yao, previously head of MedImmune's respiratory, inflammation and autoimmunity (RIA) innovative medicines unit.

"Auto-immune diseases are a group of around 80 disorders, the majority of which have no specific therapies, and they represent...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category